LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Akciju saraksts・Simulations Plus Inc

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

15.92 -0.62

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

15.44

Max

16.38

Galvenie mērījumi
By Trading Economics
Ienākumi	3.9M 4.5M
Pārdošana	5.9M 24M
EPS	0.35
Peļņas marža	18.669
Darbinieki	212
EBITDA	4.9M 7.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-0.06% downside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 13. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	70M 321M
Iepriekšējā atvēršanas cena	16.54
Iepriekšējā slēgšanas cena	15.92

Ziņu noskaņojums

By Acuity

95%

5%

319 / 344 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. jūn. 23:36 UTC

Peļņas

Correction to Oracle Reports Higher 4Q Profit Article

2026. g. 10. jūn. 23:19 UTC

Karstas akcijas

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

2026. g. 10. jūn. 23:09 UTC

Galvenie tirgus virzītāji

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

2026. g. 10. jūn. 23:04 UTC

Peļņas

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

2026. g. 10. jūn. 20:44 UTC

Galvenie tirgus virzītāji

Caterpillar Raises Quarterly Dividend 8%

2026. g. 10. jūn. 23:49 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Northern Star Should Take No Options Off The Table

2026. g. 10. jūn. 23:48 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

2026. g. 10. jūn. 23:48 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

2026. g. 10. jūn. 23:47 UTC

Tirgus saruna

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

2026. g. 10. jūn. 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

2026. g. 10. jūn. 23:46 UTC

Iegādes, apvienošanās, pārņemšana

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 10. jūn. 23:38 UTC

Tirgus saruna

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

2026. g. 10. jūn. 23:32 UTC

Tirgus saruna

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

2026. g. 10. jūn. 23:20 UTC

Tirgus saruna

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

2026. g. 10. jūn. 22:05 UTC

Tirgus saruna

Correction to Bank of Canada Stays on Hold Market Talk

2026. g. 10. jūn. 21:57 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:52 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:35 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 21:22 UTC

Peļņas

Oracle Stock Slides on Increased Capital Spending -- WSJ

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 10. jūn. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 10. jūn. 20:39 UTC

Tirgus saruna

Peļņas

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

2026. g. 10. jūn. 20:34 UTC

Peļņas

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026. g. 10. jūn. 20:33 UTC

Peļņas

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

2026. g. 10. jūn. 20:33 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 10. jūn. 20:33 UTC

Tirgus saruna

Peļņas

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-0.06% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD -0.06%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

319 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Citi krājumi no sektora

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat